Overview

Mayne Pharma Group Limited is a locally-owned, publicly listed company that derives its revenue from the product development, manufacture and distribution of pharmaceutical products. The company employs 700 people and is headquartered in Salisbury South, South Australia.

The company is listed on the ASX under the code MYX.

Mayne Pharma Group develops and manufactures the following Australian branded and generic products:

Specialty Brands

  • Astrix capsules and tablets
  • Doryx capsules
  • Eryc capsules
  • Kapanol capsules
  • Licener Single Treatment
  • Lozanoc Capsules
  • Magnoplasm Paste and Magnoplasm Splintex Gel
  • Percutane Pain Relief Cream and Percutane Sports Cream
  • Urocarb tablets

Generic Products

  • Aspirin tablets
  • Doxycycline capsules
  • Ephedrine Hydrochloride MYX
  • Epoprostenol MYX
  • Erythromycin capsules
  • Noradrenaline MYX
  • Oxycodone IR tablets
  • Water for Injection MYX

Learn more about our Company Reports

IBISWorld Company Profile Reports

Company profile reports provide key information on the Top 2000 earning companies in Australia. Reports include a written description of a company, its history, brands and products, contact details and key personnel, operating and legal structure, financial data, industries of involvement and business service providers.

Sample Data

Table of Contents

Company Details
Key Personnel
Financials
Growth & Ratios
Segments
Shareholders
Subsidiaries
Service Providers

Looking for our Industry reports?

Assess your competitors with powerful business tools that provide strategic insights and analysis on over 600 Australian industries.

Contact Us

Want to speak to a representative? Call us.

clear